Locations:
Search IconSearch
October 2, 2023/Neurosciences/Podcast

Endoscopic Surgery for Intraventricular Tumors (Podcast)

Presurgical planning and careful consideration of pathology are key to achieving benefits

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Surgical resection is the primary treatment approach for intraventricular tumors, which can be benign or malignant and additionally can affect the flow of cerebrospinal fluid and result in obstructive hydrocephalus. Minimally invasive endoscopic surgery offers several benefits over conventional methods, including reduced risk of complications and faster recovery. However, open surgery remains the best option for some pathologies.

“We don’t move completely from one option to the other; rather, we tend to expand our toolbox,” says Sarel Vorster, MD, MBA, a neurosurgeon in Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “We see endoscopic surgery not as something that is going to take over brain surgery but as another helpful option. And we find applications that are most suitable.”

In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Vorster discusses surgical management of intraventricular tumors and considerations for their endoscopic treatment, including:

  • Diagnosis of intraventricular tumors and other brain lesions
  • The process for deciding between endoscopic and conventional surgery
  • The importance of presurgical planning to ascertain the ideal trajectory through the brain
  • Tools and techniques for endoscopic surgery on intraventricular tumors
  • Technological advancements in the field

Click the podcast player above to listen to the 28-minute episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Advertisement

This activity has been approved for AMA PRA Category 1 Credit™ and ANCC contact hours. After listening to the podcast, you can claim your credit here.

Excerpt from the podcast

Dr. Vorster: If a tumor enters into a brain ventricle, it’s a whole different approach because we’re dealing with the mass effect of the lesion, or its ability to push on other structures and cause dysfunction as a result. But we’re also dealing with the biology of the tumor, so the degree of resection that’s feasible is a consideration, as is the interaction between the surgical and the oncologic approach to the lesion.

An additional consideration, which is unique to intraventricular tumors, is that the lesion is present in and around the spaces where the spinal fluid is, which raises the prospect that tumor cells could be spread around. It also raises the possibility that fluid could be blocked. For these reasons, surgeons have always been nervous about operating on lesions that go into the ventricles because of the possibility of spreading tumor cells or causing bleeding as the cells enter the fluid.That is still a concern even in contemporary practice — the risk of spreading something that might have been focal previously.

For that reason, we generally do not try to treat malignant tumors endoscopically but rather use an open approach. If a lesion is more on the benign end of the spectrum, it becomes more feasible to take an endoscopic approach. And endoscopic approaches are very appealing, of course, because of their ability, when applied appropriately, to deliver the same quality of outcome with a very small incision.

Advertisement

Related Articles

smartwatch being strapped to a woman's wrist
December 20, 2024/Neurosciences/Brain Tumor
Can Smartwatch Data Predict Progression and Detect Complications in Patients With Glioblastoma?

Researchers use AI tools to compare clinical events with continuous patient monitoring

macrophages and microglia in glioblastoma tumors
December 3, 2024/Neurosciences/Brain Tumor
Dual Targeting of Macrophages and Microglia Shows Promise in Preclinical Glioblastoma Models

Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression

photo of Elekta Esprit Gamma Knife machine
January 26, 2024/Cancer
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches

Hydrogen sulfide
Can Boosting Hydrogen Sulfide Bolster Standard-of-Care Glioblastoma Therapy to Extend Survival?

Cleveland Clinic researchers pursue answers on basic science and clinical fronts

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/Radiation Oncology
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-NEU-4229690-CQD-Podcast-Hero-650×450
Investigating Mitochondria Transfer in Glioblastoma (Podcast)

New research focuses on tumorigenic aspects of communication among brain cells

Astrocy
Mitochondria Transfer From Healthy Astrocytes Fuels Glioblastoma Tumorigenicity

Study demonstrates its role in tumor lethality, raises prospect of therapeutic targets

MRI of a patient with brain metastases
April 25, 2023/Cancer
Management of Lung Cancer Brain Metastases: An Update

We now have an expanded toolbox to extend survival and lessen treatment toxicity

Ad